Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Operational Update

13 May 2009 11:56

RNS Number : 1749S
Ovoca Gold PLC
13 May 2009
 



Ovoca Gold plc 

("Ovoca" or the "Company")

Operational update

Ovoca (London (OVG.L), Dublin (OVX.IR)) is pleased to announce an operational update.

Highlights

Ongoing planning of development activities in Pellapakh, the Company's recently discovered world-class molybdenum/copper ore body in the Kola Peninsula.

Drilling on Oleninskoye target completed with results due in June.

Continuing to review acquisition opportunities in Russia and certain other jurisdictions.

Strong liquidity position with approximately US$ 34 million in cash and Polymetal shareholding currently valued at US$ 19 million. 

Kola Properties

Ovoca holds two exploration licenses in the Kola Peninsula, Russia, which are the Company's key exploration assets. The licenses are located relatively close to infrastructure being 50 km from a hydropower station, 160 km from a large year-round seaport and 80 km from the nearest railroad station. In 2008 the Company announced the discovery of a world-class molybdenum/copper ore body named Pellapakh on one of its licenses. Ovoca is currently evaluating different development options for Pellapakh in the current low molybdenum and copper price environment. On Oleninskoye, a high-grade gold target similar in geology to active gold mines in neighbouring Finland (Suurikuusikko), 780 meters was drilled this year and the Company expects to receive back analysis of its core samples by the end of June. An announcement of these results will be made in due course.

Corporate Development

The management of Ovoca is examining acquisition opportunities for the Company. Management's acquisition strategy is to leverage the current cash shortage among the junior mining sector to the maximum benefit for Ovoca's shareholders. Management is targeting low execution risk, late development stage assets. Additionally, management is also looking at various exploration opportunities that are present in Russia in areas where the Company has expertise. These opportunities require modest current capital outlay but have world-class potential in the future. The Company is fully utilizing the strengths that it has built up over the last several years: such as a highly qualified technical team including geologists, engineers and metallurgists.

 

The Board and management are focused on keeping administration costs low to preserve the maximum amount of financial resources the Company has it its disposal for its exploration and development activities and for corporate development. The next stage of the Company's growth will be done from a corporate platform that is as efficient and lean as possible

Ovoca expects to issue its preliminary results for the year ended 31 December 2008 and announce a date for its Annual General Meeting by the middle of June 2009. At the Annual General Meeting a full Company presentation will be made to shareholders. The Company's annual report and AGM materials will be posted to shareholders in due course.

Cash and Equity Investments

In January Ovoca completed the sale of its 100 percent interest in Ayax, the owner of the Goltsovoye exploration and production licence, to JSC Polymetal ("Polymetal"). Upon completion, the disposal proceeds of US$ 11 million cash, 7.5 million Polymetal common shares and a cash payment for certain other ancillary assets and machinery equivalent to their book value of US$ 0.7 million were received in full.

Polymetal is Russia's second largest precious metals mining company and its common shares are traded on the RTS and MICEX exchanges in Russia and its global depository receipts are traded on the main market of the London Stock Exchange.

Currently, Ovoca has circa 3 million Polymetal common shares and approximately US$ 34 million in cash.

Management is exploring different ways to efficiently manage the value of its cash and securities positions and will continue to review options for its cash and equity positions to ensure returns to shareholder are optimised.

Board Composition

Ovoca is pleased to announce that Mr Mikhail Mogutov has become executive Chairman with immediate effect and in this role will actively assist the CEO in strategic and operational matters in this current exciting phase of development and opportunity for the Ovoca. 

Mr. Leonid Skoptsov CEO of Ovoca commented

"The market is extremely volatile right now, and although the precious metals sector in which we operate is one of the few areas of optimism, we feel that it makes sense to err on the side of caution. Ovoca will not rush to "do something" for the sake of being active, and we will carefully consider all options available to the company before making any decision." 

Further information is available on the Company's website at www.ovocagold.com

For further information contact

Ovoca Gold plc

Mr. Leonid Skoptsov CEO

+7 495 916 60 29

Davy (Nomad)

John Frain

+353 1 679 6363

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCCKNKPKBKDNPD
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.